Valuation dashboard for PTC Therapeutics, Inc. (PTCT) with P/E N/A, P/B -33.74, EV/EBITDA 30.47 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications.
Analysis Summary
PTC Therapeutics, Inc. reported revenue of $1.73B in the most recent fiscal year, growing at a 5-year CAGR of 35.4%.
Trailing-twelve-month margins: gross margin 82.1%, operating margin 11.5%, net margin -3.8%.
At the current price of $67.35, PTCT has negative trailing earnings (P/E not meaningful) and an ROE of 21.72%. Market capitalisation stands at $5.6B.
Balance sheet quality for PTCT: current ratio of 2.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -33.74 |
| EV / EBITDA | 30.47 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-752.03 |
| vs Current Price | -1216.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PTCT | PTC Therapeutics, Inc. | $5.6B | 21.7% | ||
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.3B | 19.78 | -0.3% | |
| PCVX | Vaxcyte, Inc. | $8.5B | 3.10 | -37.6% | |
| KRYS | Krystal Biotech, Inc. | $9.9B | 39.88 | 7.17 | |
| ACLX | Arcellx, Inc. | $6.7B | 16.10 | ||
| PTGX | Protagonist Therapeutics, Inc. | $9.2B | 8.71 | -21.2% | |
| ALKS | Alkermes plc | $7.7B | 112.07 | 4.16 | |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 7.52 | -44.2% |
Price
| Price | $67.35 |
| Market Cap | $5.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 21.72% |
| Return on Invested Capital | 2.61% |
| Return on Assets | -1.18% |
| Gross Margin | 82.14% |
| Operating Margin | 11.52% |
| Net Margin | -3.80% |
Related companies: ACLX · ALKS · ARWR · CRNX · KRYS · MTSR · PCVX
Explore sector: Healthcare · Biotechnology
More sections of PTCT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks